Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, has announced its largest and most comprehensive presence to date at the Society of Cardiovascular Computed Tomography Annual Scientific Meeting (SCCT 2026), taking place July 9-12, 2026, at the Gaylord Pacific Resort & Convention Center in Chula Vista, Calif. During the meeting, Elucid will unveil its next generation of innovation, including plaque based FFR-CT2, stenosis quantification2, and a new comprehensive user interface that enables efficient and transparent clinical insights. Across meeting proceedings, the company will present scientific and clinical cases that demonstrate its leadership in CCTA 3.0, the company’s vision of the future of CCTA-guided, personalized coronary artery disease (CAD) care.
“We are standing at an inflection point in cardiovascular medicine, on the cusp of CCTA 3.0 and moving from population-based guidelines to truly personalized therapy,” said Elucid CEO Kelly Huang, Ph.D. “Oncology made this shift over the past decade, evolving from a one-size-fits-all approach based on tumor size (anatomy) to highly personalized care driven by detailed biological characteristics and physiology of tumor behavior. Elucid’s vision is to drive a similar evolution in cardiovascular disease. At SCCT, we will demonstrate how we plan to deliver accuracy, reproducibility, and complete transparency in integrating anatomy, biology, and physiology, and how we are investing in the clinical science that will make CCTA 3.0 a reality.”
As vasodilatory function is impacted by plaque amount and composition, Elucid developed deep learning AI models that leverage its histology-based plaque quantification to estimate FFR-CT2. Elucid’s FFR-CT is validated against invasive FFR, and under review by FDA. This biointegrated approach to FFR-CT uniquely enables continuous estimation of numerical FFR-CT along the entire vessel tree in a manner that is transparent and is always concordant with plaque characterization. Additionally, Elucid offers the only CT-derived plaque analysis validated for use in the carotid arteries.
“The next frontier in coronary CT is not simply detecting disease but also measuring the biological and physiological features that determine how that disease behaves,” said Dr. Amir Ahmadi, MD, FACC, FSCCT, clinical associate professor of Cardiology at the Icahn School of Medicine at Mount Sinai and Elucid’s lead scientific advisor. “New data being presented at SCCT demonstrate that Elucid achieves excellent performance in the accurate, reproducible, and transparent quantification of plaque composition, as well as stenosis2, and plaque-derived FFR-CT1. This enables risk assessment at the level where events originate – the individual lesion – while integrating that information with vessel-level plaque burden to define personalized, patient-level risk. The goal is to translate reliable imaging data into more precise therapy and improved patient outcomes, all while improving workflow efficiency for physicians.”
Information about Elucid’s SCCT 2026 sessions and events are available at https://scct.org/page/SCCT2026
References
1 FFR-CT data being presented at SCCT is based on research product.
2 FFR-CT and stenosis are under FDA review.
